PMID- 26152804 OWN - NLM STAT- MEDLINE DCOM- 20160831 LR - 20220408 IS - 1097-0339 (Electronic) IS - 1097-0339 (Linking) VI - 43 IP - 11 DP - 2015 Nov TI - ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. PG - 941-6 LID - 10.1002/dc.23318 [doi] AB - BACKGROUND: The identification of ALK and ROS1 rearrangements and the availability of an effective target therapy, such as crizotinib, represent a new option in the treatment of advanced non-small cell lung cancer (NSCLC) patients. In light of recent advances in non-invasive diagnostic procedures, we aimed to demonstrate that direct cytological smears are suitable for assessing ALK and ROS1 rearrangements in patients with NSCLC. METHODS: Fifty-five patients with a cytological diagnosis of lung adenocarcinoma (ADC) were evaluated for ALK rearrangements by fluorescence in situ hybridization (FISH) and 12 patients for ROS1 FISH rearrangements. Seventeen of the 55 cytological samples tested for ALK were obtained from the primary tumor and 38 from metastatic lesions. Ten of 12 samples evaluated for ROS1 were obtained from metastatic sites and two from the primary tumor. RESULTS: ALK FISH was successful in 49/55 (89%) cytological ADC samples and ROS1 FISH in all 12 cytological samples. ALK rearrangements were found in 3/13 (23%) primary tumors and 7/36 (19%) metastatic sites. ROS1 rearrangements were found in one of the two primary tumors and in two of the 10 metastases. Two of the three rearranged cases were tested on cytology after knowing that they were rearranged on histology in order to increase representativeness of ROS1 rearranged cases in this study. CONCLUSION: Whenever cytology represents the only available material for diagnosis and biological characterization of NSCLC, minimally invasive procedures may provide an additional important source of cellular material for FISH assessment of ALK and ROS1 rearrangements. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Bozzetti, Cecilia AU - Bozzetti C AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Nizzoli, Rita AU - Nizzoli R AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Tiseo, Marcello AU - Tiseo M AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Squadrilli, Anna AU - Squadrilli A AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Lagrasta, Costanza AU - Lagrasta C AD - Department of Biomedical, Biotechnological and Translational Sciences, University Hospital of Parma, Parma, Italy. FAU - Buti, Sebastiano AU - Buti S AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Gasparro, Donatello AU - Gasparro D AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Zanoni, Daniele AU - Zanoni D AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Majori, Maria AU - Majori M AD - Pneumology Unit, University Hospital of Parma, Parma, Italy. FAU - De Filippo, Massimo AU - De Filippo M AD - Radiology Unit, University Hospital of Parma, Parma, Italy. FAU - Mazzoni, Francesca AU - Mazzoni F AD - Department of Medical Oncology, Careggi Hospital of Firenze, Firenze, Italy. FAU - Maddau, Cristina AU - Maddau C AD - Cytopathology Unit, Cancer Prevention and Research Institute, Firenze, Italy. FAU - Naldi, Nadia AU - Naldi N AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Sammarelli, Gabriella AU - Sammarelli G AD - Department of Clinical and Experimental Medicine, Haematology and Bone Marrow Transplantation Unit, University Hospital of Parma, Parma, Italy. FAU - Frati, Caterina AU - Frati C AD - Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy. FAU - Pinto, Carmine AU - Pinto C AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. FAU - Ardizzoni, Andrea AU - Ardizzoni A AD - Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy. LA - eng PT - Journal Article DEP - 20150707 PL - United States TA - Diagn Cytopathol JT - Diagnostic cytopathology JID - 8506895 RN - 0 (Proto-Oncogene Proteins) RN - EC 2.7.10.1 (ALK protein, human) RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - EC 2.7.10.1 (ROS1 protein, human) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) SB - IM MH - Adenocarcinoma/diagnosis/*pathology MH - Adenocarcinoma of Lung MH - Adult MH - Aged MH - Aged, 80 and over MH - Anaplastic Lymphoma Kinase MH - Carcinoma, Non-Small-Cell Lung/*metabolism/surgery MH - Cytodiagnosis/methods MH - Female MH - Gene Rearrangement/physiology MH - Humans MH - In Situ Hybridization, Fluorescence/methods MH - Lung Neoplasms/diagnosis/*metabolism/pathology/surgery MH - Male MH - Middle Aged MH - Protein-Tyrosine Kinases/*metabolism MH - Proto-Oncogene Proteins/*metabolism MH - Receptor Protein-Tyrosine Kinases/*metabolism OTO - NOTNLM OT - ALK OT - FISH OT - ROS1 OT - cytology OT - non-small cell lung cancer EDAT- 2015/07/15 06:00 MHDA- 2016/09/01 06:00 CRDT- 2015/07/09 06:00 PHST- 2015/03/12 00:00 [received] PHST- 2015/05/06 00:00 [revised] PHST- 2015/06/22 00:00 [accepted] PHST- 2015/07/09 06:00 [entrez] PHST- 2015/07/15 06:00 [pubmed] PHST- 2016/09/01 06:00 [medline] AID - 10.1002/dc.23318 [doi] PST - ppublish SO - Diagn Cytopathol. 2015 Nov;43(11):941-6. doi: 10.1002/dc.23318. Epub 2015 Jul 7.